Shares Magazine
261.60p-9.40 (-3.47%)19 Apr 2024, 10:34
Jump to:
Hutchmed (China) Limited Fundamentals
| Company Name | Hutchmed (China) Limited | Last Updated | 2024-04-19 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 853.644 m | Market Cap | £2.23 bn |
| PE Ratio | 28.12 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | $0.12 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0673 | Debt Equity Ratio | 0.0699 |
| Asset Equity Ratio | 1.7215 | Cash Equity Ratio | 1.1923 |
| Quick Ratio | 2.5711 | Current Ratio | 2.72 |
| Price To Book Value | 3.9432 | ROCE | 0 |
Hutchmed (China) Limited Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Hutchmed (China) Limited Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $104.39 m | $84.67 m | $53.15 m |
| Intangible Assets | 0 | 0 | 0 |
| Investments | $48.41 m | $73.78 m | $76.48 m |
| Total Fixed Assets | $182.93 m | $189.56 m | $160.59 m |
| Stocks | $50.26 m | $56.69 m | $35.76 m |
| Debtors | $149.91 m | $127.17 m | $132.62 m |
| Cash & Equivalents | $886.34 m | $631.00 m | $1.01 bn |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $1.28 bn | $1.03 bn | $1.37 bn |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $403.03 m | $353.90 m | $311.66 m |
| Creditors after 1 year | $133.36 m | $38.67 m | $21.49 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $536.39 m | $392.57 m | $333.15 m |
| Net assets | $743.39 m | $636.87 m | $1.04 bn |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $87.13 m | $86.48 m | $86.45 m |
| Share Premium | $1.52 bn | $1.50 bn | $1.51 bn |
| Profit / Loss | $58.31 m | -$410.42 m | -$215.74 m |
| Other Equity | $730.54 m | $610.37 m | $986.89 m |
| Preference & Minorities | $12.85 m | $26.50 m | $52.62 m |
| Total Capital Employed | $743.39 m | $636.87 m | $1.04 bn |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.07 | $0.04 | $0.01 |
| Debt-to-Equity | $0.07 | $0.04 | $0.01 |
| Assets / Equity | 1.7215 | 1.7215 | 1.7215 |
| Cash / Equity | 1.1923 | 1.1923 | 1.1923 |
| EPS | $0.12 | -$0.43 | -$0.38 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | $219.26 m | -$268.60 m | -$204.22 m |
| Cashflow before financing | $267.92 m | -$351.36 m | $445.81 m |
| Increase in Cash | -$23.22 m | -$54.77 m | $139.49 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $838.00 m | $426.41 m | $356.13 m |
| Cost of sales | $384.45 m | $311.10 m | $258.23 m |
| Gross Profit | $453.55 m | $115.31 m | $97.89 m |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | $58.31 m | -$410.42 m | -$215.74 m |
Hutchmed (China) Limited Company Background
| Sector | Healthcare |
|---|---|
| Activities | HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
| Latest Interim Date | 31 Jul 2023 |
| Latest Fiscal Year End Date | 28 Feb 2024 |
Hutchmed (China) Limited Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-04-08 | Mr. Graeme Allan Jack | Non-Executive Director |
| 2024-04-08 | Mr. Dan Eldar | Non-Executive Director |
| 2024-04-08 | Ms. Edith Shih | Non-Executive Director,Company Secretary |
| 2024-04-08 | Mr. Paul Rutherford Carter | Non-Executive Director,Senior Independent Director |
| 2017-02-01 | Mr. Christopher John Nash | Director |
| 2024-04-08 | Mr. Chi Keung Simon To | Executive Director,Chairman |
| 2022-03-03 | Mr. Christian Hogg | Executive Director,Chief Executive Officer |
| 2017-03-01 | Mr. Michael William Davis Howell | Director |
| 2017-02-01 | Professor Christopher Huang | Non-Executive Director |
| 2024-03-05 | Mr. Johnny Cheng Chig FUNG | Executive Director,Chief Financial Officer |
| 2023-05-12 | Dr. Karen Jean Ferrante, M.D. | Non-Executive Director |
| 2024-03-14 | Dr. Weiguo Su | Executive Director,Chief Executive Officer and Chief Scientific Officer |
| 2024-04-08 | Professor Shu Kam Tony Mok | Non-Executive Director |
Hutchmed (China) Limited Contact Details
| Company Name | HUTCHMED (China) Ltd |
|---|---|
| Address | Ugland House, P.O. Box 309, Grand Cayman, KY1-1104 |
| Telephone | +852 21281188 |
| Website | https://www.hutch-med.com |
Hutchmed (China) Limited Advisors
| Financial PR Adviser | BMC Communications |
|---|---|
| Phone | +1 646 513-3125 |
| Financial PR Adviser | The Trout Group |
|---|---|
| Phone | +86 15821996861 |
| Fax | +86 16463782901 |
| Registrar | Computershare Investor Services Ltd |
|---|---|
| Phone | +44 8707074040 |
| Fax | +44 3708735851 |
| Auditor | PricewaterhouseCoopers |
|---|---|
| Phone | +852 22898888 |
| Fax | +852 28109888 |
| Stockbroker | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Stockbroker | UBS Limited |
|---|---|
| Phone | +44 2075678000 |
| Solicitor | DLA Piper LLP |
|---|---|
| Phone | +44 8700111111 |
| Fax | +44 2077966666 |
| Financial PR Adviser | Citigate Dewe Rogerson |
|---|---|
| Phone | +44 2076389571 |
| Nominated Adviser | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Darktrace PLC | 474.91 | 3.60 |
| Hochschild Mining PLC | 153.20 | 1.46 |
| Endeavour Mining PLC | 1,753.00 | 1.45 |
| Croda International PLC | 4,917.00 | 1.40 |
| United Utilities Group PLC | 1,032.00 | 1.33 |
| Auction Technology Group PLC | 506.00 | 1.30 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Man Group PLC | 254.60 | -5.21 |
| Marshalls PLC | 259.00 | -3.54 |
| Discoverie Group PLC | 666.80 | -3.50 |
| Dowlais Group PLC | 77.89 | -3.06 |
| Jd Sports Fashion PLC | 116.70 | -2.99 |
| Dr. Martens PLC | 67.80 | -2.93 |